Insurance reimbursement and collections risk
Diagnostic revenue depends on payor reimbursement and timely claim collection.
- Scope
- ProPhase Diagnostics
- Materiality
- high
ProPhase Labs, Inc.
ProPhase Labs, Inc. is a U.S.-based life sciences and consumer health company with operations spanning diagnostic services, personal genomics, and branded dietary supplements. Through subsidiaries including ProPhase Diagnostics and Nebula Genomics, it combines laboratory testing, DNA sequencing, and consumer wellness products under one corporate structure.
−304,1 %
31,9 %
−339,3 %
0.06
0.06
| % | |
|---|---|
| Personal genomics | 35% Consumer DNA sequencing and genetic testing services offered through Nebula Genomics and DNA Complete. |
| Diagnostic services | 25% Laboratory testing services, including COVID-19 and other molecular diagnostics. |
| Consumer products | 30% Branded OTC health and dietary supplement products sold under the TK Supplements line. |
| Licensing and development | 10% Development and commercialization of novel drugs, compounds, diagnostics, and related IP. |
The company sells primarily to consumers seeking genetic insights, health information, and wellness products, with...
- Personal genomics consumersprimary
Buy DNA sequencing and genetic testing for ancestry, health risk, and trait insights.
- Diagnostic testing customersprimary
Buy laboratory testing services, historically including COVID-19 and molecular diagnostics.
- Supplement consumerssecondary
Buy TK Supplements products for energy, sexual vitality, and general wellness.
- Licensing and development counterpartiesemerging
Partners or license holders involved in drug, compound, and diagnostic commercialization.
ProPhase Labs is headquartered in the United States and its operating footprint is centered there, including laboratory...
- •Headquartered in the United States
- •Laboratory operations have been based in New Jersey
- •Consumer genomics and supplements are primarily U.S.-focused
- •Licensing and product development are managed from the U.S.
- •No country-level revenue disclosure was provided in the excerpts
The company is focused on building and commercializing multiple health-related businesses, including genomics,...
01
Grow personal genomics and consumer health offeringsmedium-term
These businesses provide recurring consumer-facing revenue opportunities and brand-building potential.
02
Commercialize licensed and developed assetsmedium-term
Drug, compound, and diagnostic development can create higher-value future revenue streams if successful.
03
Maintain access to capitalshort-term
The business mix includes development-stage activities that require funding before they can scale.
The company faces execution risk across several businesses, including consumer complaints, sequencing delays,...
Consumer complaints and reputational damage
DNA testing customers rely on trust, timely results, and data handling quality.
- Scope
- Nebula Genomics and DNA Complete
- Materiality
- high
Sequencing and fulfillment delays
A change in sequencing lab can delay results and increase service backlogs.
- Scope
- Personal genomics operations
- Materiality
- high
Financing and liquidity dependence
Development and commercialization activities require external capital before scale.
- Scope
- Equity, debt, and ATM financing
- Materiality
- high
Litigation and privacy exposure
Genetic data handling can trigger privacy claims and regulatory scrutiny.
- Scope
- Nebula Genomics and customer data
- Materiality
- medium
Digital asset volatility
Any crypto treasury activity can create mark-to-market and custody risk.
- Scope
- Potential digital asset holdings
- Materiality
- medium
Revenue recognition by business line
Affects quarterly comparability and reported growth across segments
Accounts receivable and claim recoverability
Can materially affect cash flow and bad debt expense
Contingent liabilities and legal reserves
Can affect expenses, liabilities, and uncertainty disclosures
Stock-based compensation
Impacts operating expenses and dilution analysis
Asset impairment and valuation
Can create non-cash charges if expected cash flows weaken
: 29.4.2026